1	Relative vaccine effectiveness (rVE) of mRNA COVID-19 boosters in the UK vaccination
2	programme, during the Spring-Summer (monovalent vaccine) and Autumn-Winter 2022
3	(bivalent vaccine) booster campaigns: a prospective test negative case-control study
4	Dr Anastasia Chatzilena PhD <sup>†</sup> , Engineering Mathematics, University of Bristol, Bristol, UK
5	Dr Catherine Hyams PhD <sup>†</sup> , Population Health Sciences, University of Bristol, Bristol, UK
6	Dr Rob Challen PhD, Engineering Mathematics, University of Bristol, Bristol, UK
7	Dr Robin Marlow PhD, Population Health Sciences, University of Bristol, Bristol, UK
8	Ms Jade King MSc, Clinical Research and Imaging Centre, UHBW NHS Trust, Bristol, UK
9 10	Mr David Adegbite BSc, Bristol Vaccine Centre, Population Health Sciences, University of Bristol, Bristol, UK
11 12	Ms Jane Kinney BSc, Bristol Vaccine Centre, Population Health Sciences, University of Bristol, Bristol, UK
13 14	Ms Madeleine Clout BSc, Bristol Vaccine Centre, Population Health Sciences, University of Bristol, Bristol, UK
15 16	Prof Nick Maskell MD, Academic Respiratory Unit, University of Bristol, Southmead Hospital, Bristol, UK
17 18	Dr Jennifer Oliver PhD, Bristol Vaccine Centre, Population Health Sciences, University of Bristol, Bristol, UK
19 20	Professor Adam Finn PhD <sup>†</sup> , Bristol Vaccine Centre, Cellular and Molecular Medicine and Population Health Sciences, University of Bristol, Bristol, UK
21 22	Dr Leon Danon PhD <sup>†</sup> , Engineering Mathematics, University of Bristol, Bristol, UK (Corresponding Author)
23	The Avon CAP Research Group
24	† These authors contributed equally, and should be considered co-first or last authors
25	
26 27	Corresponding Author:Leon Danon, PhDEngineering Mathematics, University of Bristol

28		University Walk
29		Bristol BS8 1TW
30		United Kingdom
31		+44(0)117 455 7828
32		l.danon@bristol.ac.uk
33		
34	Keywords:	COVID-19, SARS-CoV-2, respiratory infection, vaccination

### 35 ABSTRACT (241/250 words)

### 36 Background

Understanding the relative vaccine effectiveness (rVE) of new COVID-19 vaccine formulations against SARS-CoV-2 infection is an urgent public health priority. A precise comparison of the rVE of monovalent and bivalent boosters given during the 2022 Spring-Summer and Autumn-Winter campaigns, respectively, in a defined population has not been reported. We therefore assessed rVE against hospitalisation for the Spring-Summer (fourth vs third monovalent mRNA vaccine doses) and Autumn-Winter (fifth BA.1/ancestral bivalent vs fourth monovalent mRNA vaccine dose) boosters.

### 44 Methods

45 A prospective single-centre test-negative design case-control study of  $\geq$ 75 year-olds hospitalised

46 with COVID-19 or other acute respiratory disease. We conducted regression analyses controlling

47 for age, gender, socioeconomic status, patient comorbidities, community SARS-CoV-2

48 prevalence, vaccine brand and time between baseline dose and hospitalisation.

### 49 **Results**

50 682 controls and 182 cases were included in the Spring-Summer booster analysis; 572 controls

and 152 cases for the Autumn-Winter booster analysis. A monovalent mRNA COVID-19

52 vaccine as fourth dose showed rVE 46.9% (95% confidence interval [CI] 14.4-67.3) versus those

53 not boosted. A bivalent mRNA COVID-19 vaccine as fifth dose had rVE 46.4% (95%CI 17.5-

54 65), compared to a fourth monovalent mRNA COVID-19 vaccine dose.

# 55 Interpretation

- 56 Both fourth monovalent and fifth BA.1/ancestral mRNA bivalent COVID-19 vaccine doses
- 57 demonstrated benefit as a booster in older adults. Bivalent mRNA boosters offer equivalent
- 58 protection against hospitalisation with Omicron infection to monovalent mRNA boosters given
- 59 earlier in the year. These findings support the current UK immunisation programme that advises
- 60 the use of bivalent booster doses.

## 61 INTRODUCTION

Following the emergence of wild-type SARS-CoV-2 and circulation of antigenically distinct 62 63 variants, large-scale vaccination programmes were implemented to reduce overall COVID-19 64 morbidity and mortality. In the UK, several COVID-19 vaccines received rapid regulatory 65 authorisation: the vaccines used initially were the monovalent mRNA vaccine BNT162b2 66 (Cominarty®) and the ChAdOx1 (Vaxzevria®) replication-deficient simian adenovirus vector 67 vaccine, with mRNA-1273 (Spikevax®) vaccine incorporated a few months later. These three 68 COVID-19 vaccines were used in the primary campaign, with the mRNA vaccines offered as 69 boosters from September 2021 for older people, extending to all adults in November 2021. A 70 fourth dose of an mRNA vaccine was offered from March 2022 and prioritised the most 71 vulnerable: all adults aged  $\geq$ 75 years (y), and those in clinical risk groups[1]. A third priming 72 vaccine dose had already been offered to immunosuppressed individuals, so that for them, the 73 autumn 2021 and spring 2022 boosters were generally their fourth and fifth doses, respectively. 74 The COV-Boost study indicated that a fourth-dose COVID-19 mRNA vaccination boosts 75 immune responses[2], and observational studies showed three or four-dose vaccine effectiveness 76 (VE) against hospitalisation of 60.9-62.1% against BA.4 or BA.5 and 50.1% against BA.2 when 77 compared to two-doses received  $\geq 25$  weeks earlier[3]. These initial COVID-19 vaccines were 78 developed against wild-type virus and provided significant protection against infection, 79 hospitalisation, severe disease and death[4–8]. However, VE has been eroded progressively both 80 by waning of immune-protection over time and emergence of SARS-CoV-2 variants of concern 81 (VOC) (Alpha, Delta, Omicron) which show immune escape[9–12].

82

83	In summer 2022, the UK MHRA approved two new bivalent booster vaccines which were
84	developed in response to concerns about such viral evolution and escape. The Moderna bivalent
85	vaccine (Spikevax® bivalent Original/Omicron) was approved on 15th August 2022, followed
86	quickly by Pfizer/BioNTech bivalent vaccine (Comirnaty® Original/Omicron BA.1) approval on
87	3rd September 2022[13,14]. The Moderna vaccine contains 25mcg of mRNA coding for the
88	spike protein of the ancestral strain and 25mcg of mRNA against Omicron (BA.1) and the Pfizer
89	BioNTech vaccine contains 15mcg of mRNA directed against the ancestral strain and 15mcg of
90	mRNA against Omicron (BA.1). Early immunogenicity studies suggest bivalent mRNA boosters
91	induce similar or higher neutralising antibody levels against Omicron sub-variants and other
92	VOCs compared to monovalent mRNA boosters[15-19].

93

94 SARS-CoV-2 infection incidence remains high[20], whilst determining whether patients who test SARS-CoV-2 positive have COVID-19 has become increasingly challenging. Additionally, 95 96 comparison between vaccinated individuals and those who have not received any COVID-19 97 vaccine dose cannot be performed, as almost the whole population is vaccinated or had prior 98 exposure to SARS-CoV-2: thus even unvaccinated individuals have some immunity to SARS-99 CoV-2. There remains an absence of evidence of bivalent vaccines' clinical effectiveness when 100 compared to monovalent formulations because the different vaccine rollout timings make a direct 101 comparison of the vaccines impossible. Acknowledging this constraint, we undertook a test-102 negative design (TND) case control study comparing SARS-CoV-2 positive and negative acute 103 lower respiratory tract disease (aLRTD) patients, assessing the protection against SARS-CoV-2 104 hospitalisation provided by an additional monovalent or bivalent mRNA vaccine dose compared

- to those who had not received the respective doses, focusing on  $\geq$ 75y olds who were the main
- 106 target group in the spring 2022 booster programme.

# 107 METHODS

## 108 Study design and conduct

109	We estimated the relative vaccine effectiveness (rVE) of monovalent and bivalent mRNA
110	vaccines against hospitalisation in Bristol, within the study population consisting of adults
111	admitted to North Bristol and University Hospitals Bristol and Weston NHS Trusts [AvonCAP:
112	ISRCTN17354061] between 4th April 2022 and 30th July 2022 (the period following the
113	initiation of distribution of fourth dose of monovalent mRNA vaccines), and between 21st
114	September 2022 and 23rd January 2023 (the period following the initiation of distribution of
115	bivalent mRNA vaccines) inclusive. During the study period BA.4, BA.2 and BA.5 were the
116	main Omicron sub-lineages identified in COVID-19 cases in Bristol[21]. The study population
117	consisted of patients with signs/symptoms of respiratory infection, aged $\geq 18y$ at the time of
118	hospitalisation[22]. Study eligible cases and controls eligible were identified from the medical
119	admission list, and data were collected from medical records using REDCap software[23]. All
120	data collection was undertaken by individuals not involved in analysis and blinded to results,
121	following the same procedures for both cases and controls. Vaccination records for every study
122	participant were obtained from linked hospital and GP records, including vaccine brand and date
123	of administration with data collection performed by individuals blinded to participants' SARS-
124	CoV-2 test results[24].

125

126

### 128 Case definition and exclusions

- 129 We included patients with  $\geq 2$  signs of acute respiratory disease or a confirmed
- 130 clinical/radiological diagnosis of aLRTD[24]. Patients hospitalised with aLRTD and positive
- 131 admission SARS-CoV-2 test using the UKHSA diagnostic assay in use at the time were
- 132 classified as cases; those with aLRTD and negative SARS-CoV-2 result were classified as
- 133 controls. Eligible controls could have multiple hospitalisations, provided subsequent admissions
- 134 were >7 days following previous discharge. We included only the first COVID-19 admission for
- 135 each case.
- 136

137 We excluded patients whose admission date was >10 days after symptom onset date (to avoid

- 138 including potentially false negative admission SARS-CoV-2 tests), and those with a confirmed
- 139 previous SARS-CoV-2 infection. Patients who had received 2 vaccine doses or fewer at the time
- 140 of admission were also excluded (Supplementary Data S1).

141

### 142 Exposure definition

143 This analysis aims to measure the protection offered by an additional dose of monovalent

- 144 (Original 'wild-type' mRNA vaccine, Pfizer-BioNTech [Comirnaty®] or Moderna [Spikevax®])
- 145 and bivalent (Original 'wild-type'/Omicron BA.1 mRNA vaccine, Pfizer-BioNTech
- 146 [Comirnaty®] or Moderna [Spikevax®]) vaccine, each compared with those who had not
- 147 received the respective boosters, side by side, during SARS-CoV-2 Omicron variant dominance.
- 148 The Spring-Summer monovalent booster analysis (admissions 04/04/22-30/07/22) compares the

149	fourth dose of monovalent given as a booster $(21/03/22-07/08/22)$ in the UK, to the third dose of
150	monovalent vaccine during Autumn-Winter 2021 (16/09/21-14/02/22). The Autumn-Winter
151	bivalent booster analysis (admissions 21/09/22-23/01/23) compares the fifth dose of vaccine,
152	with the bivalent formulation given as a booster $(07/09/22-12/02/23)$ to the fourth dose of
153	monovalent vaccine in Spring-Summer 2022 (21/03/22-07/08/22).

154

155 For the Spring-Summer monovalent booster analysis, individuals were defined as boosted with a 156 monovalent vaccine if they had received three doses of any monovalent vaccine combination and 157 a fourth dose of monovalent vaccine during the Spring-Summer 2022 vaccination programme, 158 and no more than three months prior to their admission, and as unboosted only if they had 159 received two doses of any vaccine combination followed by a third dose of monovalent vaccine 160 during Autumn-Winter 2021. For the Autumn-Winter bivalent booster analysis, individuals were 161 defined as boosted with a bivalent vaccine if they had received four doses of any vaccine 162 combination plus a fifth bivalent dose during Spring-Summer 2022 vaccination programme and 163 no more than three months prior to their admission, and as unboosted if they had received three 164 doses of any vaccine combination plus a fourth monovalent dose during Autumn-Winter 2022. In 165 both analyses, we define those having received the most recent dose with >7 days having elapsed 166 between the vaccine and symptom onset as immunised (Supplementary Data S1).

167

The Joint Committee on Vaccination and Immunisation (JCVI) advised targeting COVID-19
booster vaccines during spring-summer towards those at highest risk of severe disease; those
aged ≥75y and residents in long-term care facilities (LTCFs)[1], while in Autumn-Winter 2022

The the offer was extended, meruaning those aged 200 y and monthline nearth and social card	171	the offer was	extended,	including t	hose aged	$\geq$ 50y and	frontline	health and	social care
---	-----	---------------	-----------	-------------	-----------	----------------	-----------	------------	-------------

- 172 workers[25]. To make a comparison of the effectiveness of the different booster vaccine
- 173 formulations, we restricted both analyses to individuals aged  $\geq$ 75y.

174

175	Individuals who received a third vaccine dose in Autumn-Winter 2021, a fourth dose in Spring-
176	Summer 2022 and a fifth dose in Autumn-Winter 2022, are those who had received two doses as
177	the primary vaccination regimen before and during Spring-Summer 2021. However, individuals
178	with severe immunosuppression around the time of their first or second vaccine doses were
179	offered an additional primary dose (third dose) before any booster doses. As a result, they were
180	offered a fourth vaccine dose in Autumn-Winter 2021, a fifth dose in Spring-Summer 2022 and a
181	sixth dose in Autumn-Winter 2022 (Figure 1, Supplementary Data S2). As additional sensitivity
182	analyses, we included individuals who had received three doses as their primary vaccination
183	regimen in both comparisons.

184

## 185 **Outcomes**

We assessed the additional protection provided by a fourth dose of mRNA monovalent vaccine
and a fifth dose of bivalent vaccine as boosters against the primary endpoint of hospital
admission with either a clinical or radiological aLRTD diagnosis or aLRTD signs/symptoms
compared to that provided by three or four doses of the monovalent formulations of the vaccines,
respectively.

191

### 192 Statistical Analysis

Demographic, clinical characteristics and other factors that may affect the exposure (vaccination
status) or outcome (hospital admission) were compared between cases and controls for both
comparisons, between monovalent vaccine boosted and not boosted, and between boosted with a
bivalent vaccine and not boosted, using Fisher exact tests (categorical variables), two-sided
Kolmogorov-Smirnov tests (continuous variables) and Wilcoxon rank-sum tests (score
variables).

199

200 Under TND assumptions, we estimate the odds ratio of testing SARS-CoV-2 positive among 201 patients boosted with a monovalent vaccine versus those not boosted (rOR) and define rVE as 202 (1-rOR)×100. Similarly, we estimated rVE of bivalent booster, comparing the odds of testing 203 positive for SARS-CoV-2 among patients boosted with a bivalent vaccine versus those not 204 boosted. This was done using univariable logistic regression (Univariable Logistic Regression 205 Model). Differences in the timing of third/fourth/fifth dose and rollout timings of different 206 vaccine brands could introduce unobserved biases, confounding results in both comparisons. To 207 mitigate these, we performed multivariable logistic regression analyses adjusting for time 208 between baseline vaccine dose and admission (in days), vaccine brand [binary variable], age, 209 gender, Index of Multiple Deprivations (IMD) decile rank and Charlson comorbidity index (CCI) 210 [continuous variable], LTCF residency status, presence of pre-existing respiratory disease, and 211 community SARS-CoV-2 prevalence lagged by time interval between infection and 212 hospitalisation, assumed to be 8-days (Multivariable Logistic Regression Model).

213

214	We also conducted sensitivity analyses, matching cases and controls using propensity score
215	balancing using logistic regression to define propensity score, and nearest neighbour matching.
216	Matching variables included age, gender, CCI and IMD, LTCF residency status and presence of
217	pre-existing respiratory disease, and likelihood of vaccine receipt (Matched Conditional Logistic
218	Regression Model). Matching by elapsed time since baseline vaccine dose/brand was not
219	performed to avoid introducing bias[26]. Time since baseline vaccine dose/ brand is affected by
220	dose of last vaccine received; each booster was deployed $\geq 4$ months after the previous COVID-
221	19 booster programme (Figure 1), with different programmes using different proportions of each
222	vaccine brand. As additional sensitivity analysis, we included individuals who had received three
223	doses as primary vaccination regimen, adjusting for the number of primary doses [binary
224	variable], using the same methods for both comparisons.

225

Statistical analyses were performed with R v4.0.2. Missing data were limited to the IMD variable and accounted for <1%; no imputation was performed; all analyses only included participants with complete data. Statistical significance was defined using a 2-sided significance level of  $\alpha$ =0.05.

230

## 231 Ethics and permissions

232 The Health Research Authority Research Ethics Committee (East of England, Essex),

233 REC20/EE/0157 approved this study, including using Section 251 of the 2006 NHS Act under

234 Confidentiality Advisory Group authorisation.

235

## 236 Role of the funding source

- 237 This study was conducted as a collaboration between The University of Bristol (study sponsor)
- and Pfizer (study funder). The study funder did not undertake any data collection, data analysis
- 239 or manuscript preparation.

### 240 **RESULTS**

241	During the periods evaluated, 9,868 adult aLRTD hospitalisations occurred in Bristol, UK, while
242	the Omicron variant was dominant[21,27,28]. In the Spring-Summer booster, 864 admissions of
243	$\geq$ 75y old patients hospitalised with SARS-CoV-2 aLRTD were eligible for this analysis: median
244	patient age was 85y (IQR 79-90), 96 individuals (53%) were male, median CCI was 5 (IQR 4-6)
245	with no significant differences in patient age, gender, demographics, and health status compared
246	to patients hospitalised with SARS-CoV-2 negative aLRTD (Figure 1, Table 1, Supplementary
247	Data S3). In the Autumn-Winter booster, 884 admissions were eligible with no significant
248	differences in gender, demographics, and health status of study eligible patients admitted with
249	SARS-CoV-2 aLRTD compared to $\geq$ 75y old patients hospitalised with SARS-CoV-2 negative
250	aLRTD (Figure 1, Table 2, Supplementary Data S4).

251

252 In the Spring-Summer booster analysis, of the 182 SARS-CoV-2 cases, 78 (43%) received a 253 fourth monovalent vaccine dose and 104 (57%) received a third monovalent vaccine dose, while 254 413 of 682 controls (61%) received a fourth monovalent vaccine dose and 269 (39%) received a 255 third monovalent vaccine dose, giving an unadjusted rVE of 51 2% (95%CI 32 1-65). The results 256 from the adjusted logistic regression model indicated that the additional protection against 257 hospitalisation was 46.9% (95%CI 14.4-67.3) when boosted with a fourth monovalent vaccine 258 dose compared to those who received only a third monovalent vaccine dose (Table 3). Matched 259 conditional logistic regression rVE was 52.4% (95%CI 21.4-71.2). Sensitivity analysis including 260 individuals with three doses as primary vaccination regimen resulted in lower rVE estimates 261 compared with results from the main analysis (Table 3, Supplementary Data S5, S6, S9).

262

263	In the Autumn-Winter booster analysis, of the 152 SARS-CoV-2 cases, 100 (66%) received a
264	fifth BA.1/ancestral bivalent vaccine dose and 52 (34%) received a fourth monovalent vaccine
265	dose, while 572 of 732 (78%) controls received a fifth bivalent vaccine dose and 160 (22%)
266	received a fourth monovalent vaccine dose, giving an unadjusted rVE of 46.2% (95%CI 21.1-
267	63). According to the adjusted logistic regression model, the adjusted rVE of a fifth bivalent
268	vaccine dose as a booster compared to a fourth monovalent vaccine dose was 46.4% (95%CI
269	17.5-65). Matched conditional logistic regression rVE was 48.5% (95%CI 19.3-67.1) (Table 4).
270	The inclusion of individuals with three doses as primary vaccination regimen produced estimates

comparable with results from the main analysis (Table 4, Supplementary Data S7, S8, S10).

## 272 DISCUSSION

273 In this analysis, we consider the public health implications of monovalent and bivalent vaccine 274 implementation, focussing on people aged  $\geq$ 75y; a high-risk group which was a primary target 275 for the UK vaccination programme. Although COVID-19 vaccines have been shown to be 276 effective against severe COVID-19 disease[4,29,30], it has not been possible to compare the 277 effectiveness of monovalent boosters directly with BA.1/ancestral bivalent booster doses of 278 mRNA COVID-19 vaccines in defined populations, because bivalent formulations rapidly and 279 entirely replaced monovalent formulations in the most recent booster programmes. In this 280 prospective study, we undertake a sequential analysis of the two vaccines given as boosters 281 during two booster programmes in the same calendar year, providing evidence that monovalent 282 vaccine (Original 'wild-type' Comirnaty® and Spikevax®) and BA.1/ancestral mRNA bivalent 283 vaccine (Original 'wild-type'/Omicron BA.1 Cominarty® and SpikeVax®) provided similar 284 additional protection over and above that afforded by previous doses without the respective 285 boosters against hospitalisation from Omicron SARS-CoV-2 sub-variants in older individuals.

286

Specifically, we estimated that receiving a fourth monovalent mRNA vaccine dose within three months was associated with a 46.9% (95%CI 14·4-67·3) relative reduction in hospitalisation risk compared to three doses, in individuals  $\geq$ 75y, during Omicron BA.2/BA.4/BA.5 lineage dominance. A fifth bivalent mRNA vaccine dose given within three months is estimated to provide 46.4% (95%CI 17·5-65) additional protection against hospitalisation compared to four doses, in the same  $\geq$ 75y age group, during a period in which alongside Omicron BA.2/BA.4/BA.5 related sublineages, the XBB recombinant lineage and its mutation XBB.1.5

294 emerged [27]. Although our results demonstrate that both vaccine formulations combined in 295 these booster programmes had benefits when used as boosters, we have insufficient case 296 numbers to draw conclusions about individual vaccine brands or directly compare them. 297 Importantly, this analysis is restricted to individuals  $\geq$ 75y old, with 97-98% of unboosted 298 individuals in our sample having received their last dose more than 3 months prior to admission 299 (Supplementary Data S2), and provides encouraging evidence of similar benefit of monovalent 300 and bivalent boosters in older adults. Older adults are at increased risk of severe disease, and 301 protection may wane faster[31]; older adults were therefore targeted in the UK Spring-Summer 302 2022 and Autumn-Winter 2022 COVID-19 booster programmes. Regarding individuals with 303 severely weakened immune systems who were eligible for three primary doses, our analysis 304 based on their inclusion in our basic comparisons, suggests that both vaccine formulations may 305 offer some additional protection.

306

307 Vaccination against SARS-CoV-2 is independently associated with lower COVID-19 308 severity[4,29,30], and vaccines have been an important disease modifier during the pandemic. 309 Our estimates suggest that the bivalent boosters provided equivalent protection as monovalent 310 boosters in a real-world setting: results concordant with early evidence suggesting neutralising 311 antibody titres induced against Omicron by a bivalent booster dose were not higher than 312 following a monovalent booster dose in small studies [16,17]. Our results are concordant with a 313 recent UKHSA analysis[32] which estimated the incremental protection conferred by a fourth 314 monovalent dose compared to waned third dose was 58.8% (95% CI 54-63%), while the 315 additional protection of BA.1/ancestral mRNA bivalent vaccines relative to those with  $\geq 2$  doses 316 and waned protection was 57% (95% CI 48-65%), during the same time period as our analysis.

317

318	Since the study took place over the course of two different time periods, the interpretation of this
319	sequential comparison of the two vaccine formulations has to take into account the different
320	variants circulating[21,27,28]. Currently, there is no evidence that Omicron BA.2-related
321	sublineages, Omicron BA.5-related sublineages and XBB recombinant-related sublineages,
322	which appeared during the study period of the BA.1/ancestral mRNA bivalent boosters, cause
323	more severe disease. The impact of these lineages on the effectiveness of the BA.1/ancestral
324	mRNA bivalent formulation has not yet been studied in detail.

325

326 The TND has been described previously, along with its advantages and limitations[12,24,33], 327 and our analysis has some important additional strengths and limitations. The strength of our 328 approach is the focus on using real-world data, while accounting for the potential effects of 329 vaccine waning, and comorbidities. By limiting our analysis to boosted individuals only, our 330 analysis sidesteps the potentially unfair comparisons between populations that have followed UK 331 COVID-19 vaccine recommendations and unvaccinated populations that may display other 332 idiosyncratic behaviours. We also utilised symptom onset date to define illness start time and are 333 able to confirm that there is no difference in time since vaccination between the case and control 334 groups compared. We, therefore, define illness onset relative to both vaccination and 335 hospitalisation date accurately, without relying on positive test date (which may vary widely), 336 eliminating this source of bias or misclassification. All patients were hospitalised with acute 337 respiratory illness, so these results are unlikely to be subject to significant bias caused by 338 admission for other causes (i.e., incidental COVID-19 disease). Most notably, our estimates for

339	the effect of individual vaccines are underpowered, due to small patient numbers in our cohort
340	during the phases of the UK vaccination programme and study periods. We are unable to assess
341	additional protection against other markers of disease severity, such as admission to intensive
342	care or requirement for respiratory support, due to the small number of eligible admissions in this
343	time period. This analysis does not measure rVE in individuals who were not hospitalised or
344	were asymptomatic, so we cannot determine protection against asymptomatic disease or
345	transmission. Treatment biases may result in community-based treatment, death before
346	admission, or patients may otherwise not be referred to hospital. We note that this cohort, whilst
347	broadly representative of the UK population, was predominantly Caucasian and the studied
348	vaccines may have different effectiveness in individuals from other ethnic backgrounds.
349	
350	In this prospective study, we provide evidence that autumn BA.1/ancestral mRNA bivalent
351	COVID-19 boosters offered equivalent augmentation of protection against Omicron
352	hospitalisation to that induced by spring monovalent mRNA boosters in 2022. Our findings
353	support the current UK immunisation programme, that advises the use of bivalent booster doses

354 in high-risk individuals.

## 355 FIGURE LEGENDS

356

## 357 Figure One: Study Flow Diagram

- 358 (A) Inclusion and exclusion criteria in the cohort. Of the 55 SARS-CoV-2 positive individuals,
- 359 33 were vaccinated with 5/6th dose bivalent mRNA vaccine, and 22 were vaccinated with 5/6th
- dose monovalent mRNA vaccine. Of the 350 SARS-CoV-2 negative individuals admitted, 269
- 361 were vaccinated with 5/6th dose bivalent mRNA vaccine and 81 were vaccinated with 5/6th dose
- 362 monovalent mRNA vaccine. (B) Study timeline

## 363 Data Sharing

364 The data used in this study are sensitive and cannot be made publicly available without 365 breaching patient confidentiality rules. The data dictionary is therefore unavailable.

366

#### 367 Contributors

368 AC, CH, RC, RM, LD, JO, and AF generated the research questions and analysis plan. CH, JK,

369 JK, MC, DA and The AvonCAP team were involved in data collection. AC, CH, RM, RC, LD,

and AF undertook data analysis. All authors (AC, CH, RC, RM, JK, DA, JK, MC, NM, JO, LD,

AF) were involved in the final manuscript preparation and its revisions before publication. The

data was verified by CH, DA, MC, JK and JK. AF provided oversight of the research.

373

### **374 Declarations of Interest**

375 CH is Principal Investigator of the AvonCAP study which is an investigator-led University of 376 Bristol study funded by Pfizer and has previously received support from the NIHR in an 377 Academic Clinical Fellowship. JO and LD are Co-Investigators on the AvonCAP Study. AF is a 378 member of the Joint Committee on Vaccination and Immunization (JCVI) and, until December 379 2022 was chair of the World Health Organization European Technical Advisory Group of 380 Experts on Immunization (ETAGE) committee. In addition to receiving funding from Pfizer as 381 Chief Investigator of this study, he leads another project investigating transmission of respiratory

bacteria in families jointly funded by Pfizer and the Gates Foundation. The other authors have norelevant conflicts of interest to declare.

384

#### 385 Acknowledgements

386 We thank Jennifer Nguyen, Joanna Southern, Bradford Gessner, John McLaughlin, Gillian 387 Ellsbury, Kaijie Pan, Luis Jodar, Elizabeth Begier, the UKHSA Vaccine Effectiveness Working 388 Group and the University of Bristol UNCOVER group for guidance in study design and data 389 analysis. We thank colleagues for their support with this study, including Rachel Davies, Paul 390 Savage, Emma Foose, Susan Christie, Mark Mummé, and Adam Taylor. We also thank the research teams at North Bristol and University Hospitals of Bristol and Weston NHS Trusts for 391 392 making this study possible, including Helen Lewis-White, Rebecca Smith, Rajeka Lazarus, Mark 393 Lyttle, Kelly Turner, Jane Blazeby, Diana Benton, and David Wynick and all participants of the 394 many studies undertaken to find effective vaccines against SARS-CoV-2. LD and RC gratefully 395 acknowledge support from UKRI through the JUNIPER consortium (grant number 396 MR/V038613/1). LD is further supported through MRC (grant number MC/PC/19067), EPSRC 397 (EP/V051555/1).

398

### **399 The AvonCAP Research Group:**

400 Anna Morley, Amelia Langdon, Anabella Turner, Anya Mattocks, Bethany Osborne, Charli

401 Grimes, Claire Mitchell, David Adegbite, Emma Bridgeman, Emma Scott, Fiona Perkins,

402 Francesca Bayley, Gabriella Ruffino, Gabriella Valentine, Grace Tilzey, James Campling,

- 403 Johanna Kellett Wright, Julia Brzezinska, Julie Cloake, Katarina Milutinovic, Kate Helliker,
- 404 Katie Maughan, Kazminder Fox, Konstantina Minou, Lana Ward, Leah Fleming, Leigh
- 405 Morrison, Lily Smart, Louise Wright, Lucy Grimwood, Maddalena Bellavia, Madeleine Clout,
- 406 Marianne Vasquez, Maria Garcia Gonzalez, Milo Jeenes-Flanagan, Natalie Chang, Niall Grace,
- 407 Nicola Manning, Oliver Griffiths, Pip Croxford, Peter Sequenza, Rajeka Lazarus, Rhian Walters,
- 408 Robin Marlow, Robyn Heath, Rupert Antico, Sandi Nammuni Arachchge, Seevakumar Suppiah,
- 409 Taslima Mona, Tawassal Riaz, Vicki Mackay, Zandile Maseko, Zoe Taylor, Zsolt Friedrich,
- 410 Zsuzsa Szasz-Benczur.

411

## 413 **REFERENCES**

- 414 1. Joint Committee on Vaccination and Immunisation (JCVI) statement on COVID-19
- 415 vaccinations in 2022: 21 February 2022. https://www.gov.uk/government/publications/joint-
- 416 committee-on-vaccination-and-immunisation-statement-on-covid-19-vaccinations-in-2022/joint-
- 417 committee-on-vaccination-and-immunisation-jcvi-statement-on-covid-19-vaccinations-in-2022-
- 418 21-february-2022.
- 419 2. Munro APS, Feng S, Janani L, Cornelius V, Aley PK, Babbage G, et al. Safety,
- 420 immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given
  421 as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third
- 422 dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trial. Lancet
- 423 Infect Dis. 2022;22:1131–41.
- 424 3. Kirsebom FCM, Andrews N, Stowe J, Groves N, Chand M, Ramsay M, et al. Effectiveness of
- the COVID-19 vaccines against hospitalisation with Omicron sub-lineages BA.4 and BA.5 in
- 426 England. Lancet Reg Health Eur. Elsevier; 2022;23.
- 427 4. Lauring AS, Tenforde MW, Chappell JD, Gaglani M, Ginde AA, McNeal T, et al. Clinical
- severity of, and effectiveness of mRNA vaccines against, covid-19 from omicron, delta, and
   alpha SARS-CoV-2 variants in the United States: prospective observational study. BMJ. British
- 429 appla SARS-COV-2 variants in the Onited States: prospective observational study. Divis.430 Medical Journal Publishing Group; 2022;376:e069761.
- 5. Nordström P, Ballin M, Nordström A. Risk of infection, hospitalisation, and death up to 9
  months after a second dose of COVID-19 vaccine: a retrospective, total population cohort study
  in Sweden. Lancet Lond Engl. 2022;399:814–23.
- 455 III Swedeli. Lancet Lond Eligi. 2022,399.814–25.
- 434 6. Chung H, He S, Nasreen S, Sundaram ME, Buchan SA, Wilson SE, et al. Effectiveness of
- BNT162b2 and mRNA-1273 covid-19 vaccines against symptomatic SARS-CoV-2 infection and
  severe covid-19 outcomes in Ontario, Canada: test negative design study. BMJ. British Medical
  Journal Publishing Group; 2021;374:n1943.
- 438 7. Andrews N, Stowe J, Kirsebom F, Toffa S, Sachdeva R, Gower C, et al. Effectiveness of
- 439 COVID-19 booster vaccines against COVID-19-related symptoms, hospitalization and death in
   440 England. Nat Med. 2022;28:831–7.
- 8. Tseng HF, Ackerson BK, Luo Y, Sy LS, Talarico CA, Tian Y, et al. Effectiveness of mRNA1273 against SARS-CoV-2 Omicron and Delta variants. Nat Med. 2022;28:1063–71.
- 9. Britton A, Fleming-Dutra KE, Shang N, Smith ZR, Dorji T, Derado G, et al. Association of
  COVID-19 Vaccination With Symptomatic SARS-CoV-2 Infection by Time Since Vaccination
  and Delta Variant Predominance. JAMA. 2022;327:1032–41.
- 446 10. Lin D-Y, Gu Y, Xu Y, Wheeler B, Young H, Sunny SK, et al. Association of Primary and
- Booster Vaccination and Prior Infection With SARS-CoV-2 Infection and Severe COVID-19
  Outcomes. JAMA. 2022;328:1415–26.

- 449 11. Ferdinands JM, Rao S, Dixon BE, Mitchell PK, DeSilva MB, Irving SA, et al. Waning 2-
- 450 Dose and 3-Dose Effectiveness of mRNA Vaccines Against COVID-19-Associated Emergency
- 451 Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of
- 452 Delta and Omicron Variant Predominance VISION Network, 10 States, August 2021-January
- 453 2022. MMWR Morb Mortal Wkly Rep. 2022;71:255–63.
- 454 12. Andrews N, Tessier E, Stowe J, Gower C, Kirsebom F, Simmons R, et al. Duration of
- 455 Protection against Mild and Severe Disease by Covid-19 Vaccines. N Engl J Med.
- 456 2022;386:340–50.
- 457 13. Regulatory approval of Spikevax bivalent Original/Omicron booster vaccine.
- 458 https://www.gov.uk/government/publications/regulatory-approval-of-spikevax-bivalent-
- 459 originalomicron-booster-vaccine.
- 460 14. Regulatory approval of Pfizer/BioNTech bivalent Original/Omicron booster vaccines.
- 461 https://www.gov.uk/government/publications/regulatory-approval-of-pfizerbiontech-bivalent 462 originalomicron-booster-vaccine.
- 15. Chalkias S, Harper C, Vrbicky K, Walsh SR, Essink B, Brosz A, et al. A Bivalent OmicronContaining Booster Vaccine against Covid-19. N Engl J Med. 2022;387:1279–91.
- 16. Collier AY, Miller J, Hachmann NP, McMahan K, Liu J, Bondzie EA, et al. Immunogenicity
  of the BA.5 Bivalent mRNA Vaccine Boosters. bioRxiv. 2022;2022.10.24.513619.
- 467 17. Wang Q, Bowen A, Valdez R, Gherasim C, Gordon A, Liu L, et al. Antibody responses to
  468 Omicron BA.4/BA.5 bivalent mRNA vaccine booster shot. bioRxiv. 2022;2022.10.22.513349.
- 469 18. Davis-Gardner ME, Lai L, Wali B, Samaha H, Solis D, Lee M, et al. mRNA bivalent booster
  470 enhances neutralization against BA.2.75.2 and BQ.1.1. bioRxiv. 2022;2022.10.31.514636.
- 471 19. Kurhade C, Zou J, Xia H, Liu M, Chang HC, Ren P, et al. Low neutralization of SARS-CoV-
- 472 2 Omicron BA.2.75.2, BQ.1.1, and XBB.1 by parental mRNA vaccine or a BA.5-bivalent
  473 booster. Nat Med. 2022;1–1.
- 474 20. England Summary | Coronavirus (COVID-19) in the UK. https://coronavirus.data.gov.uk.
  475 2023.
- 476 21. Lineages (raw) | COVID-19 Genomic Surveillance Wellcome Sanger Institute.
- $\label{eq:2.1} \mbox{ https://covid19.sanger.ac.uk/lineages/raw?p_type=line&area=E06000023\&lineageView=1\&View=1Wiew=1Wiew$
- 478 ages=A%2CB%2CB.1.177%2CB.1.1.529%2CBA.4%2CBA.5%2CBA.2&colours=7%2C3%2C
- 479 0%2C6%2C2%2C4%2C1&show=B.1.1.529%2CBA.4%2CBA.5%2CBA.2.
- 480 22. Hyams C, Challen R, Begier E, Southern J, King J, Morley A, et al. Incidence of community
- 481 acquired lower respiratory tract disease in Bristol, UK during the COVID-19 pandemic: A
- 482 prospective cohort study. Lancet Reg Health Eur. Elsevier; 2022;21.

483 23. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data

484 capture (REDCap)—A metadata-driven methodology and workflow process for providing
 485 translational research informatics support. J Biomed Inform. 2009;42:377–81.

486 24. Hyams C, Marlow R, Maseko Z, King J, Ward L, Fox K, et al. Effectiveness of BNT162b2

- 487 and ChAdOx1 nCoV-19 COVID-19 vaccination at preventing hospitalisations in people aged at
- least 80 years: a test-negative, case-control study. Lancet Infect Dis. Elsevier; 2021;21:1539–48.
- 489 25. JCVI statement on the COVID-19 booster vaccination programme for autumn 2022: update 3
- 490 September 2022. https://www.gov.uk/government/publications/covid-19-vaccines-for-autumn-
- 491 2022-jcvi-advice-15-august-2022/jcvi-statement-on-the-covid-19-booster-vaccination-
- 492 programme-for-autumn-2022-update-15-august-2022.
- 493 26. Greenland S. Quantifying biases in causal models: classical confounding vs collider494 stratification bias. Epidemiol Camb Mass. 2003;14:300–6.
- 495 27. SARS-CoV-2 variants of concern and variants under investigation in England: Technical496 briefing 50.
- 497 28. Wright DW, Harvey WT, Hughes J, Cox M, Peacock TP, Colquhoun R, et al. Tracking
  498 SARS-CoV-2 mutations and variants through the COG-UK-Mutation Explorer. Virus Evol.
  499 2022;8:veac023.
- 500 29. Hyams C, Challen R, Marlow R, Nguyen J, Begier E, Southern J, et al. Severity of Omicron
- 501 (B.1.1.529) and Delta (B.1.617.2) SARS-CoV-2 infection among hospitalised adults: A
- prospective cohort study in Bristol, United Kingdom. Lancet Reg Health Eur. 2023;25:100556.
- 30. Nyberg T, Ferguson NM, Nash SG, Webster HH, Flaxman S, Andrews N, et al. Comparative
  analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron
  (B.1.1.529) and delta (B.1.617.2) variants in England: a cohort study. The Lancet.
- 506 2022;399:1303–12.
- 507 31. Cerqueira-Silva T, Oliveira V de A, Boaventura VS, Pescarini JM, Júnior JB, Machado TM,
- tal. Influence of age on the effectiveness and duration of protection of Vaxzevria and
- 509 CoronaVac vaccines: A population-based study. Lancet Reg Health Am. Elsevier; 2022;6.
- 510 32. COVID-19 vaccine surveillance report: week 5.
- 511 https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment\_data/file
- 512 /1134076/vaccine-surveillance-report-week-5-2023.pdf.
- 513 33. Chatzilena A, Hyams C, Challen R, Marlow R, King J, Adegbite D, et al. Effectiveness of
- 514 BNT162b2 COVID-19 vaccination in prevention of hospitalisations and severe disease in adults
- 515 with SARS-CoV-2 Delta (B.1.617.2) and Omicron (B.1.1.529) variant between June 2021 and
- 516 July 2022: A prospective test negative case–control study. Lancet Reg Health Eur.
- 517 2023;25:100552.
- 518





В